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Abstract
Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable
anti-tumor responses within and outside the radiation field. There has been a rapid expansion in the number of clinical
trials harnessing radiation to enhance antitumor immunity. If positive, results of these trials will lead to a
paradigm shift in the use of radiotherapy. In this review, we discuss the rationale for trials combining radiation
with various immunotherapies, provide an update of recent clinical trial results and highlight trials currently in
progress. We also address issues pertaining to the optimal incorporation of immunotherapy with radiation,
including sequencing of treatment, radiation dosing and evaluation of clinical trial endpoints.
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Introduction
Radiation therapy (RT) is a longstanding pillar of cancer
treatment, historically utilized to treat a discrete target
and provide local tumor control. Mounting evidence
demonstrates that RT also elicits an immune response
that can manifest as an immune-mediated tumor regres-
sion outside of the targeted site [1]. The potential ability
of RT to induce an immunogenic cell death and coun-
teract an immune-suppressive tumor microenvironment
to effectively convert the irradiated tumor into an in situ
vaccine has implications for both local and systemic dis-
ease control, and provides the primary rationale for
combining novel immunotherapies with RT.
The combination of immunotherapy with RT is an ac-
tively growing field of clinical investigation, with rapid
expansion in the number and type of clinical trials. After
a brief summary on the immunomodulatory properties
of radiation, this review will describe some of the avail-
able types of immunotherapies that are currently being
tested in combination with radiotherapy. We will discuss
the challenges in the design and evaluation of current
trials, including selection of appropriate radiation dose,
fractionation, sequencing of therapies and meaningful
trial endpoints.
Radiation and immune-mediated tumor response
Historically, RT has been considered to be immunosup-
pressive, based on older treatment techniques with large
fields that included substantial bone marrow volume
and/or circulating blood volume resulting in reduced
blood cell counts [2, 3]. In addition, because of the rela-
tive radio-sensitivity of hematopoietic cells, whole-body
RT regimens are used prior to stem cell transplantation
to cause lympho- and myelo-ablation [4, 5].
To minimize side effects to normal tissue, conven-
tional treatment regimens deliver the radiation dose that
is effective at controlling a tumor (40 to 70 Gy, depend-
ing on tumor type) in multiple small daily doses, given
over several weeks. Advancements in RT equipment and
planning systems allow delivery of highly conformal
treatment with increased precision, and as a result, it is
now possible to deliver higher doses per fraction while
sparing adjacent normal tissue. Techniques such as
stereotactic radiosurgery and body radiation therapy (SRS,
SBRT), intensity modulated radiation therapy (IMRT) and
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image-guided radiation therapy (IGRT) have transformed
delivery of RT, broadening the range of RT applications.
Since the effects of radiation on the immune system and
on the tumor microenvironment may depend on the dose
and delivery methods used, when radiation is used to
stimulate an anti-tumor immune response in combination
with immunotherapy thoughtful considerations on deliv-
ery techniques, dose, and fractionation are warranted.
The traditional model of radiation-induced tumor con-
trol that forms the basis for conventional fractionated
RT regimens is built on four well-established principles
of radiobiology, the fours “Rs”: reassortment of cells to a
cell cycle phase that is radiation-sensitive after each frac-
tion; repair of sublethal damage in normal cells to de-
crease toxicity, reoxygenation of hypoxic tumor regions,
and repopulation [6]. In this model, the therapeutic ef-
fect of radiation is mainly attributed to direct DNA dam-
age and indirect damage from free radical formation [7].
However, preclinical studies over the past decade have
demonstrated an important contribution from the effects
of RT on the tumor microenvironment and on the anti-
tumor immune response, giving rise to the concept that
the fifth “R” of radiobiology is immune-mediated tumor
Rejection [8].
The multitude of biological responses elicited by RT
that have been shown in experimental models to convert
the irradiated tumor into an in situ vaccine have been
detailed in several recent reviews [9–11]. Here, we will
only briefly highlight a few concepts that more signifi-
cantly impact clinical trial design. In vitro, immunogenic
cell death (ICD) is induced by RT in a dose-dependent
way [12], suggesting that larger doses should have more
pro-immunogenic effects. However, in vivo data suggest
a more complex relationship with dose and fraction-
ation. The ability of RT to induce priming of anti-tumor
T cells is influenced by the pre-existing tumor micro-
environment, and by the effects of RT on immune cells
and other components of the tumor microenvironment
[7]. So far, pre-clinical studies have not achieved a con-
sensus about the optimal dose and regimen to be used
to stimulate the immune system, with some studies sup-
porting the use a single large doses (e.g., 30 Gy), and
others showing that standard dose of 2 Gy or classical
hypo-fractionated doses of 6 or 8 Gy delivered daily in
consecutive days are more effective [13–15]. Importantly,
radiation-induced T cell responses to immunogenic ex-
ogenous antigens (e.g., ovalbumin) expressed by tumors at
relatively high levels were demonstrated [16]. However, in
other experiments induction of T cell responses to shared
tumor antigens derived from self-proteins that are over-
expressed by cancer cells could not be detected unless
mice were given immunotherapy to overcome key im-
munosuppressive pathways [10]. Thus, while several types
of immunotherapy have been shown to work in concert
with RT to induce anti-tumor T cell responses, [9] the
requirements for a specific combination to be effective,
in terms of RT dose and fractionation and sequencing
of RT with immunotherapy have not been fully explored
in pre-clinical studies, leaving multiple open questions for
optimal design of a clinical study.
In the next paragraphs, we will succinctly describe the
available immunotherapies, then focus on active clinical
trials that are investigating their synergy with radiation.
Immunotherapy: new therapeutic opportunities
Significant progress in immuno-oncology has led to new
treatments such as immune checkpoint blockade, adop-
tive T cell transfer, cytokine therapy, dendritic cell and
peptide vaccines, and monoclonal antibody treatment.
Many of these immunotherapies have been tested in com-
bination with RT in pre-clinical studies and are under in-
vestigation in the clinic.
Induction of anti-tumor immunity is a multi-step
process, which is regulated at every step by positive and
negative signals [17]. First, tumor antigens must reach
professional antigen-presenting cells (APCs), such as
dendritic cells, which upon activation migrate to draining
lymph nodes. There, DCs, after processing the peptides in
the proteasome, present them as part of the major histo-
compatibility (MHC) molecules to T cells, in the context
of co-stimulatory signals that result in T cell activation
and proliferation. Once activated, tumor-specific T cells
differentiate into effectors and home to the tumor where
they must overcome the existing immune-suppressive
microenvironment to successfully reject it. Other T
cells differentiate into memory T cells, potentially cap-
able to protect the host from micrometastatic disease
that emerges from dormancy and prevent tumor recur-
rence [18]. Immunotherapies currently approved and in
development act at one or more of the steps of this
process. RT has been shown to potentially enhance
each step, including uptake of tumor antigens by den-
dritic cells and their activation, as well as migration of
the activated effector T cells back to the tumor. Thus
RT could enhance and complement the action of many
different immunotherapy agents [19–21].
Some of the emerging therapies are summarized below,
along with combination approaches incorporating RT.
Immune checkpoint blockade
Immune checkpoints trigger downstream signaling
pathways that inhibit T cells activation and/or effector
function and maintain a balance between stimulation
and suppression of immune function, thereby preventing
autoimmunity. Antibodies against two immune check-
points have been approved by FDA for treatment of some
cancers.
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Cytotoxic T-lymphocyte antigen 4 (CTLA-4) CTLA-4
is an inhibitory receptor that is upregulated after T-cell
activation, and transmits signals that suppress T-cell ac-
tivation and proliferation [22]. It is also expressed at
high levels on tumor-infiltrating regulatory T cells (Tregs)
and antibodies targeting CTLA-4 can selectively deplete
these cells by antibody-mediated cellular cytotoxicity
(ADCC) mechanisms [23].
One antibody targeting CTLA-4, ipilimumab (Yervoy,
Bristol Myers Squibb), is approved for metastatic melan-
oma [24]. Tremelimumab is another anti-CTLA-4 antibody
currently under development by MedImmune/Astra
Zeneca.
A seminal preclinical study demonstrated that RT is
synergistic with anti-CTLA antibody and induces systemic
anti-tumor responses in a poorly immunogenic carcinoma
refractory to anti-CTLA-4 monotherapy [25]. Since that
time, there have been multiple case reports and retro-
spective series reporting abscopal effects in patients re-
ceiving RT during treatment with ipilimumab [26–29].
Dose and fractionation schedule likely play an import-
ant role in response. Preclinical models support use of
hypofractionated RT in daily doses of 6 to 8 Gy given 5
or 3 times, over a single high dose treatment of 20 Gy,
in order to maximize likelihood of generating an effect-
ive anti-tumor immune response with anti-CTLA-4 [15].
Consistent with this finding, the most dramatic cases of
abscopal effect reported with ipilimumab and RT have
utilized RT doses and fractionation [26, 27, 29, 30] simi-
lar to the RT regimens effective in preclinical studies.
However, abscopal effects were also reported in patients
treated with a wider range of RT doses [26, 29, 31].
While most abscopal responses reported with addition
of RT to ipilimumab were in melanoma, a disease respon-
sive to ipilimumab alone, a notable exception was a pa-
tient with metastatic non-small cell lung cancer (NSCLC)
resistant to multiple lines of systemic chemotherapy who
was treated with ipilimumab and 5 fractions of 6 Gy RT to
a single liver metastasis [30]. This resulted in a complete
and durable response. A phase 2 study evaluating this
regimen (NCT02221739) in NSCLC completed enroll-
ment and confirmed the activity of RT + ipilimumab in
a disease that was non-responsive to anti-CTLA-4
alone [32].
A phase 1 dose escalation trial (NCT01497808) evalu-
ated 22 patients with metastatic melanoma, treated with
2-3 fractions of RT to a single lung or osseous metasta-
sis, or 6 Gy to a subcutaneous or hepatic metastasis,
followed by ipilimumab [33]. There were no complete
responses, though partial responses were noted in 18 %
of unirradiated lesions. However, given that ipilimumab
at baseline has activity in metastatic melanoma, it is un-
certain the degree to which RT contributed to tumor
regression.
A phase 1/2 trial enrolled men with metastatic castrate-
resistant prostate cancer, and escalated the dose of ipili-
mumab, with or without concurrent single fraction RT
(8 Gy) targeting an osseous metastasis [34]. This approach
was further evaluated in a subsequent, multi-institutional,
phase 3 trial (NCT00861614) with 799 patients diagnosed
with metastatic castrate-resistant prostate cancer, treated
with 1 fraction (8 Gy) RT to an osseous metastasis and
randomized to ipilimumab or placebo [35]. Primary end-
point of improved overall survival was not achieved,
though P-value was close to the cut off for significance
(P = 0.0530). On subset analysis, patients with non-visceral
metastatic disease treated with ipilimumab combined with
RT experienced an incremental improvement in overall
survival, suggesting non-visceral metastases may be a
more appropriate target for RT in combination with
ipilimumab. Furthermore, this study demonstrated that
the combination of RT and ipilimumab was overall
well-tolerated with minimal added toxicity.
Currently ongoing trials combining CTLA-4 inhibition
with RT are summarized in Table 1. Metastatic melanoma
is the most common primary diagnosis under study,
and majority of studies are evaluating RT and CTLA-4
blockade administered in concurrent fashion.
Programmed death-1 (PD-1)/Programmed death
ligand -1(PD-L1) PD-1 is an inhibitory cell surface re-
ceptor that acts as an immune checkpoint. Its ligand, PD-
L1 is expressed on diverse types of cells, including
antigen-presenting cells, epithelial and endothelial cells.
Studies have shown that PD-1 and PD-L1 targeted therap-
ies have clinical activity against metastatic bladder cancer,
head and neck cancers, Hodgkin’s lymphoma, non-small
cell lung cancer, and renal cell cancer [36]. Anti-PD-1
therapies, pembrolizumab (MK-3475/Keytruda, Merck &
Co) and nivolumab (Opdivo, Bristol-Meyers Squibb Co),
are currently approved as treatment for unresectable or
metastatic melanoma, and as second-line treatment for
non-small cell lung cancer (NSCLC) after chemotherapy.
Nivolumab has been recently approved for Hodgkin’s
lymphoma that has relapsed or progressed after autolo-
gous hematopoietic stem cell transplantation, and meta-
static renal cell carcinoma. Atezolizumab (MPDL3280A)
and durvalumab (MEDI-4736) are monoclonal anti PD-L1
antibodies currently under active investigation in clinical
trials. Atezolizumab has been recently approved by FDA
for locally advanced or metastatic urothelial carcinoma
progressing during or after platinum chemotherapy.
REGN2810 is a monoclonal antibody that binds to PD-1
and inhibits PD-L1 mediated activation of downstream
pathways.
Preclinical studies demonstrate that the combination
of RT and targeted PD-1/PD-L1 therapy activates cyto-
toxic T-cells, reduces myeloid-derived suppressor cells
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Table 1 Active clinical trials combining radiation with CTLA-4 inhibition
NCT Number Phase Title Conditions Interventions RT Details Enrollment Sponsor/Collaborators
NCT01711515 Phase 1 Chemoradiation Therapy and
Ipilimumab in Treating Patients
With Locally Advanced Cervical
Cancer
Cervical Cancer Cisplatin, Ipilimumab EBRT 6 weeks 28 National Cancer Institute (NCI)
NCT02406183 Phase 1 Trial of SBRT With Concurrent
Ipilimumab in Metastatic
Melanoma
Melanoma Ipilimumab SBRT 8-12 Gy × 3 fx 21 Radiotherapie|University Hospital,
Ghent
NCT01935921 Phase 1 Ipilimumab, Cetuximab, and
Intensity-Modulated Radiation
Therapy in Treating Patients With
Previously Untreated Stage





IMRT, 7 wks 18 National Cancer Institute (NCI)
NCT02659540 Phase 1 A Pilot Study to Evaluate the
Safety and Efficacy of
Combination Checkpoint Blockade
Plus External Beam Radiotherapy
in Subjects With Stage IV Melanoma
Melanoma Ipilimumab,
Nivolumab
EBRT 3 Gy × 10 fx
or 9 Gy × 3 fx
18 Ludwig Institute for Cancer
Research|Bristol-Myers Squibb
NCT01860430 Phase 1 A Phase Ib Trial of Concurrent
Cetuximab (ERBITUX) and Intensity
Modulated Radiotherapy (IMRT)
With Ipilimumab (YERVOY) in Locally





IMRT, 7 wks 18 University of Pittsburgh|National
Cancer Institute (NCI)
NCT01996202 Phase 1 A Pilot Study of Ipilumimab and
Radiation in Poor Prognosis
Melanoma
Melanoma Ipilimumab EBRT 24 Duke University
NCT02311361 Phase 1 Immune Checkpoint Inhibition
(Tremelimumab and/or MEDI4736)
in Combination With Radiation




SBRT, 1-5 fx 60 National Cancer Institute (NCI)|National
Institutes of Health Clinical Center (CC)
NCT02239900 Phase 1|Phase 2 Ipilimumab and Stereotactic Body




Ipilimumab SBRT 12.5 Gy × 4 fx 120 M.D. Anderson Cancer Center|Bristol-
Myers Squibb
NCT02696993 Phase 1|Phase 2 Phase I/II Trial of Nivolumab With
Radiation or Nivolumab and
Ipilimumab With Radiation for the
Treatment of Intracranial Metastases





WBRT 3 Gy × 10 fx,
SRS 1 fxa
80 M.D. Anderson Cancer Center|Bristol-
Myers Squibb
NCT02254772 Phase 1|Phase 2 TLR9 Agonist SD-101, Ipilimumab,
and Radiation Therapy in Treating
Patients With Low-Grade Recurrent
B-cell Lymphoma
B-cell Lymphoma Ipilimumab, TLR9
agonist SD-101
RT days 1, 2 27 Ronald Levy|National Cancer Institute
(NCI)|Stanford University
NCT01565837 Phase 2 SART: Concurrent Ipilimumab and
Stereotactic Ablative Radiation
Melanoma Ipilimumab SBRT 1-5 fx 50 Wolfram Samlowski|Comprehensive














Table 1 Active clinical trials combining radiation with CTLA-4 inhibition (Continued)
Therapy (SART) for Oligometastatic
But Unresectable Melanoma
NCT01970527 Phase 2 Phase II Trial of Stereotactic Body
Radiotherapy Followed by




Ipilimumab SBRT 3 fx 40
NCT02107755 Phase 2 Stereotactic Radiation Therapy and
Ipilimumab in Treating Patients With
Metastatic Melanoma
Melanoma Ipilimumab SBRT 32 Ohio State University Comprehensive
Cancer Center|Bristol-Myers Squibb
NCT02097732 Phase 2 Ipilimumab Induction in Patients




Ipilimumab SRS 1 fxa 40 University of Michigan Cancer Center
NCT02115139 Phase 2 GRAY-B: GEM STUDY: Radiation And
Yervoy in Patients With Melanoma
and Brain Metastases
Melanoma Ipilimumab WBRT 3 Gy × 10 fx 66 Grupo Espanol Multidisciplinar de
Melanoma|Bristol-Myers Squibb
NCT02701400 Phase 2 Tremelimumab and Durvalumab
With or Without Radiation Therapy






SBRT 20 Emory University|AstraZeneca
NCT02434081 Phase 2 NICOLAS: NIvolumab COnsolidation
After Standard First-line
Chemotherapy and Radiotherapy
in Locally Advanced Stage IIIA/B
NSCLC
NSCLC Nivolumab EBRT 43 European Thoracic Oncology Platform|
Bristol-Myers Squibb|Frontier Science
Foundation, Hellas





Ipilimumab Palliative RT 20 Stanford University
aDose determined by treating physician















and induces an abscopal response [14, 37, 38]. Based on
these promising results, numerous ongoing clinical trials
are testing the combination of PD-1/PD-L1 inhibition
and RT (Table 2). Majority of studies are phase 1 or 2.
There are two open phase 3 trials looking at combin-
ation of nivolumab with RT in locally advanced NSCLC
(NCT02768558), and glioblastoma (NCT02617589), re-
spectively; results are pending.
Transforming growth factor beta (TGFβ) targeting
TGFβ is a cytokine with immunosuppressive activity
that is activated by RT in the tumor microenvironment
[39–41]. Preclinical studies have shown that inhibition
of TGFb during and after RT allows priming of T cells
to multiple tumor antigens leading to immune-mediated
regression of the irradiated tumor and non-irradiated me-
tastases [41]. A few clinical studies are ongoing to test the
benefits of TGFβ inhibition and RT (Table 3). One phase
1/2 trial in patients with metastatic breast tested the use
of a neutralizing antibody, fresolimumab, with RT and is
closed to accrual (NCT01401062). A second trial in the
same patient population is accruing and uses a small mol-
ecule inhibitor, LY2157299, to target the TGFb receptor
(NCT02538471). Fresolimumab is also being tested in the
SABR-ATAC phase 1/2 trial in patients with stage IA/IB
non-small cell lung cancer with the primary endpoint of
evaluating late RT-induced fibrosis inhibition in the phase
2 study (NCT02581787). Another phase 2 study testing
LY2157299 in rectal cancer in combination with chemo-
therapy and RT is not yet open (NCT02688712). A phase
1b/2a study in testing chemoRT and LY2157299 in glioma
patients has completed accrual (NCT01220271).
Cytokines
Granulocyte macrophage colony-stimulating factor
(GM-CSF) GM-CSF is a growth factor secreted by mac-
rophages, T-cells, NK cells, endothelial cells and fibro-
blasts, promoting maturation of dendritic cells and
enabling cross-presentation of tumor cell antigens to
generate memory T-cells. Preclinical data supports the
combination of RT and cytokines to generate an absco-
pal effect [42]. Based on this, a proof-of-principle pilot
study was initiated with 10 fractions of RT (3.5 Gy per
fraction) directed to a metastatic lesion and 14 days of
GM-CSF. Out of 41 patients with varied tumor histolo-
gies, 11 (26.8 %) exhibited clinical response outside of
the RT field [43].
GM-CSF gene-transduced tumor cells have shown prom-
ise as vaccines (GVAX), demonstrating durable tumor re-
gression in clinical trials enrolling patients with advanced
NSCLC, and reports of tumor regression in patients with
renal cell carcinoma and melanoma [44]. Currently on-
going trials utilizing GM-CSF or GVAX with radiation are
summarized in Table 3. There are far fewer studies for
GM-CSF in combination with RT in comparison to
immune check point inhibitors.
Interleukin-2 (IL-2) IL-2 is a cytokine produced by
T-cells that stimulates T-cell proliferation and antigen-
specific differentiation. Treatment with high-dose IL-2 has
been documented to induce a complete response in pa-
tients with metastatic renal cell carcinoma (RCC), and
promote tumor regression in melanoma, but only a small
percentage of patients respond [45, 46]. Preclinical data
suggests that RT can promote memory T-cell formation
through release of cytokines and upregulation of MHC-1,
[47, 48] providing rationale for a phase 1 study that com-
bined 1-3 fractions of RT (20 Gy per fraction) with high
dose IL-2 for patients with metastatic RCC and melan-
oma. Response to treatment was correlated with a statisti-
cally significant increase in proliferating early activated
effector memory T-cells [49]. Although IL-2 has shown
promising potential in a subset of patients, there are
significant toxicities associated with treatment, ranging
from flu-like symptoms to vascular leak syndrome,
which is the most frequent and severe complication of
treatment [50, 51].
Currently, four phase 2 clinical trials are investigating
the combination of high-dose IL-2 with SBRT in 1-3
fractions of 6-20 Gy each, enrolling patients with meta-
static melanoma or RCC (Table 4). There are also phase
1 and 2 trials evaluating use of a recombinant fusion
protein consisting of IL-2 with L19 human vascular target-
ing antibody (Darleukin, L19-IL2), which promotes lympho-
cyte and NK cell stimulation and immune-mediated tumor
cell death, with less toxicity [52–55]. This is delivered
together with ablative doses of radiation in patients with
oligometastatic or limited metastatic disease. Ongoing
trials are summarized in Table 4.
Interferon alpha (IFN-α) Interferon alpha (IFN-α) gen-
erated interest after preliminary studies demonstrated a
survival advantage in pancreatic cancer patients, result-
ing in a phase 2 trial (NCT00059826) combining IFN-α
with adjuvant chemoRT in resected pancreatic cancer
patients [56]. Although the observed median survival of
25.4 months was promising compared to historical stan-
dards, the regimen had considerable high-grade toxicity,
resulting in early closure of the study.
Results of a phase 2 trial (NCT01276730) randomizing
locally advanced cervical cancer patients to RT with cis-
platin versus IFN-α plus retinoic acid were recently re-
ported [57]. Primary endpoint was overall survival at
3 years. Unfortunately, there was no survival advantage
demonstrable with the addition of IFN-α, though toxicity
was acceptable. There is currently one actively recruiting
phase 2 study (ABSIDE, NCT01973322), randomizing pa-
tients with metastatic melanoma to four different arms,
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Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy
NCT Number Phase Title Conditions RT Details Enrollment Sponsor/Collaborators
NCT02642809 Phase 0 Pembrolizumab With Locally
Delivered Radiation Therapy
for the Initial Treatment of
Metastatic Esophageal Cancers
Esophageal Cancer Hypofx brachytherapy 15 Washington University School of
Medicine|Merck Sharp & Dohme Corp.
NCT02463994 Phase 0 A Pilot Study of MPDL3280A
and HIGRT in Metastatic NSCLC
NSCLC Hypofx RT 12 University of Michigan Cancer
Center|University of Washington
NCT02587455 Phase 1 Pembrolizumab and Palliative
Radiotherapy in Lung
Thoracic Tumours Palliative EBRT 48 Royal Marsden NHS Foundation
Trust|Merck Sharp & Dohme Corp.
NCT02608385 Phase 1 Study of PD1 Blockade by
Pembrolizumab With
Stereotactic Body Radiotherapy
in Advanced Solid Tumors
NSCLC SBRT, 3-5 fx 138 University of Chicago
NCT02621398 Phase 1 Pembrolizumab, Paclitaxel,
Carboplatin, and Radiation
Therapy in Treating Patients
With Stage II-IIIB NSCLC
NSCLC EBRT 30 Rutgers, The State University of New
Jersey|National Cancer Institute
(NCI)|Merck Sharp & Dohme Corp.





Malignant Glioma FSRT over 5 days 32 H. Lee Moffitt Cancer Center and
Research Institute|Merck Sharp &
Dohme Corp.
NCT02402920 Phase 1 Phase I Trial of MK-3475 and
Concurrent Chemo/Radiation
for the Elimination of Small
Cell Lung Cancer
Lung Cancer EBRT, 1.5 Gy × 30 fx, BID 80 M.D. Anderson Cancer Center|Merck
Sharp & Dohme Corp.
NCT02716948 Phase 1 Stereotactic Radiosurgery and
Nivolumab in Treating Patients
With Newly Diagnosed
Melanoma Metastases in the
Brain or Spine
Melanoma (Brain metastases) SRS 90 Sidney Kimmel Comprehensive
Cancer Center
NCT02560636 Phase 1 Pembrolizumab in Muscle
Invasive/Metastatic Bladder
Cancer
Invasive Bladder Cancer Hypofx RT 34 Royal Marsden NHS Foundation
Trust|Merck Sharp & Dohme Corp.
NCT02318771 Phase 1 Radiation Therapy and MK-3475
for Patients With Recurrent/
Metastatic Head and Neck
Cancer, Renal Cell Cancer,
Melanoma, and Lung Cancer
Metastatic HN, RCC, Melanoma,
Lung Cancer
EBRT 40 Thomas Jefferson University|Merck
Sharp & Dohme Corp.
NCT02648633 Phase 1 Stereotactic Radiosurgery With
Nivolumab and Valproate in
Patients With Recurrent
Glioblastoma
Glioblastoma SRS 17 University of Virginia
NCT02303366 Phase 1 Pilot Study of Stereotactic
Ablation for Oligometastatic















Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy (Continued)
Breast Neoplasia in Combination
With the Anti-PD-1 Antibody
MK-3475
NCT02659540 Phase 1 A Pilot Study to Evaluate the
Safety and Efficacy of Combination
Checkpoint Blockade Plus External
Beam Radiotherapy in Subjects
With Stage IV Melanoma
Melanoma 3 Gy × 10 fx, or 9 Gy × 3 fx 18 Ludwig Institute for Cancer
Research|Bristol-Myers Squibb
NCT02586207 Phase 1 Pembrolizumab in Combination
With CRT for LA-SCCHN
Advanced HN Cancers EBRT, 7 wks 39 Sanford Health|Merck Sharp & Dohme
Corp.
NCT02303990 Phase 1 RADVAX: A Stratified Phase I Trial
of Pembrolizumab With
Hypofractionated Radiotherapy in
Patients With Advanced and
Metastatic Cancers
Metastatic Cancers Hypofx RT 70 Abramson Cancer Center of the
University of Pennsylvania
NCT02764593 Phase 1 Chemotherapy +/- Nivolumab in
Patients With Intermediate and
High-Risk Local-Regionally
Advanced Head and Neck
Squamous Cell Carcinoma
Advanced HN Cancers IMRT, 7 wks 120 RTOG Foundation, Inc.|Bristol-Myers
Squibb
NCT02400814 Phase 1 MPDL3280A and Stereotactic
Ablative Radiotherapy in Patients
With NSCLC
NSCLC SBRT, 5 fx 45 University of California, Davis|National
Cancer Institute (NCI)|Genentech, Inc.
NCT02383212 Phase 1 Study of REGN2810 (Anti-PD-1) in
Patients With Advanced
Malignancies
Advanced Cancer Hypofx RT 973 Regeneron Pharmaceuticals|Sanofi
NCT02311361 Phase 1 Immune Checkpoint Inhibition
(Tremelimumab and/or MEDI4736)
in Combination With Radiation
Therapy in Patients With
Unresectable Pancreatic Cancer
Pancreatic Cancer SBRT, 1-5 fx 60 National Cancer Institute (NCI)|National
Institutes of Health Clinical Center (CC)
NCT02696993 Phase 1|Phase 2 Phase I/II Trial of Nivolumab With
Radiation or Nivolumab and
Ipilimumab With Radiation for the
Treatment of Intracranial
Metastases From NSCLC
Lung Cancer (Brain metastases) WBRT 3 Gy × 10 fx, SRS 1 fx 80 M.D. Anderson Cancer Center|Bristol-
Myers Squibb
NCT02444741 Phase 1|Phase 2 MK-3475 and Hypofractionated
Stereotactic Radiation Therapy in
Patients With NSCLC (NSCLC)
Lung Cancer EBRT or SBRT 104 M.D. Anderson Cancer Center|Merck
Sharp & Dohme Corp.
NCT02530502 Phase 1|Phase 2 Radiation Therapy With
Temozolomide and Pembrolizumab
in Treating Patients With Newly
Diagnosed Glioblastoma
Glioblastoma EBRT 50 Northwestern University|Merck Sharp
& Dohme Corp.|National Cancer
Institute (NCI)
NCT02730546 Phase 1|Phase 2 Pembrolizumab, Combination
Chemotherapy, and Radiation















Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy (Continued)
Therapy Before Surgery in Treating
Adult Patients With Locally
Advanced Gastroesophageal
Junction or Gastric Cardia Cancer
That Can Be Removed by Surgery




Advanced HN Cancers EBRT 47 Nooshin Hashemi-Sadraei|Merck Sharp
& Dohme Corp.|University of Cincinnati
NCT02407171 Phase 1|Phase 2 Evaluating the Combination of
MK-3475 and Sterotactic Body
Radiotherapy in Patients With
Metastatic Melanoma or NSCLC
Melanoma, Lung Cancer SBRT, 1-5 fx 60 Yale University
NCT02735239 Phase 1|Phase 2 Study of Anti-PD-L1 in
Combination With Chemo(Radio)
Therapy for Oesophageal Cancer
Esophageal Cancer EBRT 75 Ludwig Institute for Cancer Research|
AstraZeneca
NCT02305186 Phase 1|Phase 2 Safety and Immunological Effect
of Pembrolizumab in Resectable
or Borderline Resectable Pancreatic
Cancer
Pancreatic Cancer EBRT, 1.8 Gy × 28 fx 56 Osama Rahma, MD|M.D. Anderson
Cancer Center|University of Virginia
NCT02599779 Phase 2 A Proof of Principle Study of
Pembrolizumab With SBRT in TKI
mRCC Patients
Metastatic RCC SBRT 35 Sunnybrook Health Sciences Centre|
Merck Sharp & Dohme Corp.|Ozmosis
Research Inc.
NCT02648282 Phase 2 Study With CY, Pembrolizumab,
GVAX, and SBRT in Patients With
Locally Advanced Pancreatic
Cancer
Pancreatic Cancer SBRT, 3-5 fx 54 Sidney Kimmel Comprehensive Cancer
Center|Merck Sharp & Dohme Corp.
NCT02492568 Phase 2 Pembrolizumab After SBRT Versus
Pembrolizumab Alone in
Advanced NSCLC
NSCLC SBRT, 8 Gy × 3 fx 74 The Netherlands Cancer Institute|Merck
Sharp & Dohme Corp.
NCT02641093 Phase 2 Phase II Trial of Adjuvant Cisplatin
and Radiation With Pembrolizumab
in Resected Head and Neck
Squamous Cell Carcinoma
HN Cancer EBRT, 6 wks 80 Trisha Wise-Draper|Merck Sharp &
Dohme Corp.|University of Cincinnati
NCT02684253 Phase 2 Screening Trial of Nivolumab With
Image Guided, Stereotactic Body
Radiotherapy (SBRT) Versus
Nivolumab Alone in Patients With
Metastatic Head and Neck
Squamous Cell Carcinoma (HNSCC)
HN Cancer SBRT, 9 Gy x 3 fx 40 Memorial Sloan Kettering Cancer
Center|University of Chicago
NCT02667587 Phase 2 Study of Temozolomide Plus
Radiation Therapy With Nivolumab
or Placebo, for Newly Diagnosed
Patients With Glioblastoma (GBM,
a Malignant Brain Cancer).















Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy (Continued)
NCT02437071 Phase 2 Assess the Efficacy of Pembrolizumab
Plus Radiotherapy or Ablation in
Metastatic Colorectal Cancer Patients
Metastatic Colorectal Cancer EBRT vs radiofrequency ablation 48 Memorial Sloan Kettering Cancer
Center|Merck Sharp & Dohme Corp.
NCT02658097 Phase 2 A Randomized Two Arm Phase II
Trial of Pembrolizumab Alone or
Sequentially Following Single
Fraction Non-ablative Radiation to
One of the Target Lesions, in
Previously Treated Patients With
Stage IV NSCLC
Stage IV NSCLC 8 Gy × 1 fx 66 Case Comprehensive Cancer Center
NCT02562625 Phase 2 Trial of Pembrolizumab and
Radiotherapy in Melanoma
Melanoma 8 Gy × 3 fx 234 Royal Marsden NHS Foundation
Trust|University of Manchester|
University of Leeds
NCT02730130 Phase 2 Study to Assess the Efficacy of
Pembrolizumab Plus Radiotherapy
in Metastatic Triple Negative Breast
Cancer Patients
Metastatic Breast Cancer EBRT 17 Memorial Sloan Kettering Cancer
Center|Merck Sharp & Dohme Corp.
NCT02707588 Phase 2 Tolerance and Efficacy of
Pembrolizumab or Cetuximab
Combined With RT in Patients
With Locally Advanced HNSCC
Advanced HN Cancers EBRT 114 Groupe Oncologie Radiotherapie
Tete et Cou




Urothelial Cancer of the Bladder
Muscle-invasive Urothelial
Cancer of the Bladder
Hypofx RT 54 New York University School of
Medicine|Merck Sharp & Dohme
Corp.
NCT02609503 Phase 2 Pembrolizumab + Radiation for
Locally Adv SCC of the Head and
Neck (SCCHN) Not Eligible Cisplatin
Head and Neck Cancer IMRT, 7 wks 29 UNC Lineberger Comprehensive
Cancer Center|Merck Sharp & Dohme
Corp.
NCT02677155 Phase 2 Sequential Intranodal Immunotherapy
(SIIT) Combined With Anti-PD1
(Pembrolizumab) in Follicular
Lymphoma
Follicular Lymphoma 8 Gy × 1 fx 20 Oslo University Hospital|Norwegian
Cancer Society|Merck Sharp & Dohme
Corp.
NCT02586610 Phase 2 Trial of Chemoradiation and
Pembrolizumab in Patients With
Rectal Cancer
Rectal Cancer EBRT, 1.8 Gy × 28 fx 53 Osama Rahma, MD|Hoosier Cancer
Research Network|Merck Sharp &
Dohme Corp.
NCT02434081 Phase 2 NIvolumab COnsolidation After
Standard First-line Chemotherapy
and Radiotherapy in Locally
Advanced Stage IIIA/B NSCLC
NSCLC EBRT 43 European Thoracic Oncology Platform|
Bristol-Myers Squibb|Frontier Science
Foundation, Hellas
NCT02296684 Phase 2 Immunotherapy With MK-3475 in
Surgically Resectable Head and
Neck Squamous Cell Carcinoma
HN Cancer IMRT, 6 wks 46 Washington University School of














Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy (Continued)
NCT02499367 Phase 2 Nivolumab After Induction
Treatment in Triple-negative Breast
Cancer (TNBC) Patients
Breast Cancer 20 Gy × 1, or 8 Gy × 3 84 The Netherlands Cancer Institute|Bristol-
Myers Squibb
NCT02635360 Phase 2 Pembrolizumab and Chemoradiation
Treatment for Advanced Cervical
Cancer
Cervical Cancer EBRT + brachytherapy 88 Linda R Duska|Merck Sharp & Dohme
Corp.|University of Virginia
NCT02662062 Phase 2 Pembrolizumab With
Chemoradiotherapy as Treatment
for Muscle Invasive Bladder Cancer
Bladder Cancer EBRT, 6 wks 30 Australian and New Zealand Urogenital
and Prostate Cancer Trials Group
NCT02336165 Phase 2 Phase 2 Study of MEDI4736 in
Patients With Glioblastoma
Glioblastoma EBRT 108 Ludwig Institute for Cancer Research|
MedImmune LLC
NCT02289209 Phase 2 Reirradiation With MK-3475
(Pembrolizumab) in Locoregional
Inoperable Recurrence or Second
Primary Squamous Cell CA of the
Head and Neck
Recurrent HN Cancers EBRT 48 Dan Zandberg|Merck Sharp & Dohme
Corp.|University of Maryland
NCT02768558 Phase 3 Cisplatin and Etoposide Plus
Radiation Followed By Nivolumab/
Placebo For Locally Advanced
NSCLC
NSCLC EBRT (IMRT or 3D CRT) 660 RTOG Foundation, Inc.|Bristol-Myers
Squibb
NCT02617589 Phase 3 Study of Nivolumab Versus
Temozolomide, Given With
Radiation Therapy, for Newly-
diagnosed Patients With
Glioblastoma (GBM, a Malignant
Brain Cancer)
Brain Cancer EBRT 550 Bristol-Myers Squibb|Ono
Pharmaceutical Co. Ltd
Abbreviations: 3D CRT 3-dimensional conformal radiation therapy, EBRT external beam radiation in conventional fractions, fx fractions, hypofx hypofractionated, IMRT intensity modulated radiation therapy, FSRT fractionated














Table 3 Active clinical trials combining radiation with TGF-β blockade or GM-CSF
NCT Number Phases Title Condition Intervention RT Details Enrollment Sponsor/Collaborators
Anti-TGF- β
NCT02538471 Phase 2 LY2157299 Monohydrate (LY2157299)









SABR-ATAC: A Trial of TGF-beta Inhibition
and Stereotactic Ablative Radiotherapy for
Early Stage Non-small Cell Lung Cancer
Stage IA-B NSCLC Fresolimumab SBRT, 4 fx 60 Maximilian Diehn|National Cancer
Institute (NCI)|Stanford University
GM-CSF
NCT02623595 Phase 2 A Study of SBRT in Combination With
rhGM-CSF for Stage IV NSCLC Patients
Who Failed in Second-line Chemotherapy
Non-small cell
lung cancer
GM-CSF SBRT, 10 Gy × 5 fx 60 Wuhan University|Tongji Hospital|Hubei
Cancer Hospital
NCT02663440 Phase 2 Trial of Hypofractionated Intensity
Modulated Radiation Therapy With
Temozolomide and Granulocyte-macrophage
Colony-stimulating Factor for Patients With
Newly Diagnosed Glioblastoma Multiforme
Glioblastoma GM-CSF, Temozolomide Hypofx IMRT 41 Zhejiang Cancer Hospital
NCT02677155 Phase 2 Sequential Intranodal Immunotherapy (SIIT)







8 Gy × 1 20 Oslo University Hospital|Norwegian
Cancer Society|Merck Sharp &
Dohme Corp.
NCT02648282 Phase 2 Study With CY, Pembrolizumab, GVAX, and






SBRT, 6.6 Gy × 5 fx 54 Sidney Kimmel Comprehensive
Cancer Center|Merck Sharp &
Dohme Corp.














Table 4 Active clinical trials combining radiation, miscellaneous
NCT Number Phase Title Conditions Interventions RT Details Enrollment Sponsor/Collaborators
Interleukin 2
NCT02086721 Phase 1 Phase I Clinical Study
Combining L19-IL2 With
SABR in Patients With
Oligometastatic Solid Tumor
Solid Tumour L19-IL-2 (recombinant
protein with IL-2)
SBRT, 7.5-30 Gy in 1-8 fx 18 Maastricht Radiation Oncology
NCT01416831 Phase 2 Comparison of High-dose
IL-2 and High-dose IL-2 With
Radiation Therapy in Patients
With Metastatic Melanoma.
Metastatic Melanoma IL-2 SBRT, 20 Gy × 1-2 fx 44 Providence Health & Services|
Prometheus
NCT01896271 Phase 2 High Dose IL-2 and Stereotactic
Ablative Body Radiation Therapy
for Metastatic Renal Cancer
Metastatic RCC, Melanoma IL-2 SBRT, 8-20 Gy in 1-3 fx 26 University of Texas
Southwestern Medical Center|
Prometheus
NCT01884961 Phase 2 Radiotherapy as an Immunological
Booster in Patients With Metastatic
Melanoma or Renal Cell Carcinoma
Treated With High-dose Interleukin-2
Metastatic RCC, Melanoma IL-2 SBRT, 6-12 Gy × 3 fx 19 Istituto Scientifico Romagnolo
per lo Studio e la cura dei
Tumori
NCT02306954 Phase 2 Study of High Dose Interleukin-2
(IL-2) and Stereotactic Body Radiation
(SBRT) in Patients With Metastatic
Renal Cancer
Renal Cell Carcinoma IL-2 SBRT, 20 Gy × 2 fx 84 Providence Health & Services|
Prometheus Laboratories
NCT02735850 Phase 2 Combination of SABR and L19-IL2
in Patients With Stage IV Lung
Cancer (ImmunoSABR)
Stage IV NSCLC, Limited
Metastatic Disease
L19-IL-2 SBRT 141 Maastricht Radiation Oncology
Other Cytokines
NCT01973322 Phase 2 Vaccination With Autologous
Dendritic Cells Loaded With
Autologous Tumor Lysate or
Homogenate Combined With
Immunomodulating Radiotherapy
and/or Preleukapheresis IFN-alfa in
Patients With Metastatic Melanoma:
a Randomized “Proof-of-principle”
Phase II Study (ABSIDE)
Metastatic Melanoma IFN-alfa IMRT, 8-12 Gy in 3 fx 24 Istituto Scientifico Romagnolo
per lo Studio e la cura dei
Tumori
OX40 agonists
NCT01862900 Phase 1|Phase 2 Phase I/II Study of Stereotactic Body
Radiation Therapy to Metastatic
Lesions in the Liver or Lung in
Combination With Monoclonal
Antibody to OX40 (MEDI6469) in
Patients With Progressive Metastatic
Breast Cancer After Systemic Therapy
Metastatic Breast Cancer OX40 antibody
(MEDI6469)
SBRT, 10-25 Gy in 1-2
fractions
40 Providence Health & Services
TLR agonists
NCT02180698 Phase 1 TLR4 Agonist GLA-SE and Radiation
Therapy in Treating Patients With















Table 4 Active clinical trials combining radiation, miscellaneous (Continued)
Soft Tissue Sarcoma That Is Metastatic
or Cannot Be Removed by Surgery
NCT02061449 Phase 1 Poly ICLC, Radiation, and Romidepsin




TLR3 agonist Poly-ICLC RT, 3 fx 24 New York University School of
Medicine|Ludwig Institute for
Cancer Research
NCT02254772 Phase 1|Phase 2 TLR9 Agonist SD-101, Ipilimumab,
and Radiation Therapy in Treating
Patients With Low-Grade Recurrent
B-cell Lymphoma
Recurrent Lymphoma TLR-9 agonist (SD-101),
Ipilimumab
local RT 27 Ronald Levy|National Cancer
Institute (NCI)|Stanford
University
NCT01421017 Phase 1|Phase 2 Toll-like Receptor (TLR) 7 Agonist,
Cyclophosphamide, and Radiotherapy
for Breast Cancer With Skin Metastases
Metastatic Breast Cancer TLR-7 agonist Imiquimod,
Cyclophosphamide
RT, 6 Gy × 5 fx 55 New York University School of
Medicine|National Cancer
Institute (NCI)
NCT01976585 Phase 1|Phase 2 In Situ Vaccine for Low-Grade
Lymphoma: Combination of




Low dose RT 30 Joshua Brody|Icahn School of
Medicine at Mount Sinai
Cancer Vaccines
NCT01436968 Phase 3 Phase 3 Study of ProstAtak™
Immunotherapy With Standard
Radiation Therapy for Localized
Prostate Cancer
Prostate cancer AdV-tk vs placebo,
valacyclovir +/- ADT
EBRT, 8 wks 711 Advantagene
NCT02446093 Phase 1|Phase 2 Neoadjuvant GMCI Plus mFOLFIRINOX
and Chemoradiation for Non-
Metastatic Pancreatic Adenocarcinoma
(PaTK02)
Pancreatic cancer AdV-tk, mFOLFIRINOX,
gemcitabine
EBRT 44 Ohio State University
NCT01833208 Radiation Therapy in Treating Patients
With Metastatic Hormone-Resistant
Prostate Cancer Receiving Sipuleucel-T
Metastatic Prostate Cancer Sipuleucel-T High-dose 1 fx to bony
metastasis
15 Roswell Park Cancer Institute|
National Cancer Institute
(NCI)|Dendreon
NCT01818986 Phase 2 Sipuleucel-T and Stereotactic Ablative
Body Radiation (SABR) for Metastatic
Castrate-resistant Prostate Cancer
(mCRPC)
Metastatic Prostate Cancer Sipuleucel-T SBRT, metastatic site 41 University of Texas
Southwestern Medical Center
NCT02232230 Phase 2 A Multicenter Trial Enrolling Men
With Advanced Prostate Cancer
Who Are to Receive Combination
Radiation and Sipuleucel-T















with one of the arms exploring use of IFNα with a den-
dritic cell vaccine and RT, 8-12 Gy in 3 fractions; results
are pending.
Tumor necrosis factor alpha (TNF-α) TNF-α is a cyto-
kine produced by activated macrophages and other im-
mune cells, inducing diverse effects such as immune cell
activation and tumor cell apoptosis. Initial studies incorp-
orating TNF-α with radiation resulted in unacceptably
high rates of toxicity [58]. TNFerade is an adenovector-
based gene therapy agent, wich allows radiation-induced
translation of TNF- α via a radiation-inducible promoter.
Studies using TNFerade intratumoral injection with RT
showed acceptable toxicity, [59] providing stimulus for
subsequent phase 1 and 2 studies exploring the com-
bination of TNFerade with RT in different primary can-
cers. Phase 1 studies suggested improved overall and
progression-free survival in esophageal cancer, head
and neck cancer and other solid tumors [60–64]. This
resulted in a phase 3 randomized trial for locally advanced
pancreatic cancer patients, treated with standard of care
(SOC) chemoRT, vs SOC +TNFerade [65]. Levels of grade
3-4 toxicity were similar between the two arms, but there
was no improvement in median survival with the addition
of TNFerade. This dampened enthusiasm for this novel
approach, and there are currently no open studies explor-
ing TNFerade with RT.
Costimulatory antibodies
OX40 agonists OX40 (CD134) is a member of the TNF
receptor superfamily, expressed on activated CD4+ and
CD8+ T-cells, and induced on activated regulatory T-cells,
NK cells and neutrophils [66]. Stimulation of OX40 re-
sults in proliferation of CD4+, CD8+ T cells, cytokine pro-
duction and memory T cell promotion, and suppression of
regulatory T-cells, making it an attractive target for com-
bination strategies with RT. Preclinical studies combining
single fraction RT (20 Gy) with OX40 activation have
demonstrated increased survival and disease regression,
correlating with increased tumor infiltration by CD8+
T-cells [67, 68]. The ability of OX40 to enhance T-cell
memory and proliferation, while suppressing regulatory
T-cell function in preclinical models resulted in enthu-
siasm for the combination of OX40 agonists with RT,
surgery or systemic agents [69]. A phase 1 clinical trial
testing an antibody agonist of OX40 with cyclophos-
phamide and single fraction RT (8 Gy) in metastatic
prostate cancer patients is currently ongoing, though
no longer recruiting (NCT01642290). Results of the im-
munological analysis were reported in abstract form in
2013, [70] and showed increased proliferation of CD4+,
CD8+ and NK cells in peripheral blood lymphocytes,
along with increased interferon gamma and IL-2. There
was no change in proliferation of regulatory T-cells.
There is also a phase 1/2 trial combining monoclonal
antibody agonist of OX40 (MEDI6469) with SBRT in 1-2
fractions of 10-25 Gy each in breast cancer patients with
lung or liver metastases (NCT01862900).
Dendritic cells (DCs)
The first category of DC-based immunotherapy entails
intratumoral injection of autologous DCs to promote
the cross priming of T cells to tumor antigens after RT,
and increase tumor infiltration of CD8+ T-cells [71].
This approach has been utilized in a phase 1 trial in pa-
tients with hepatocellular carcinoma who were treated
with single fraction RT (8 Gy) and injected with autolo-
gous DCs two days later. Out of 14 patients, 50 % dem-
onstrated a minor to partial clinical response [72].
Another phase I study (NCT00365872) evaluated intra-
tumoral DC injection with neoadjuvant RT to 50 Gy in
25 fractions in soft tissue sarcoma, with primary endpoint
to evaluate immunologic response [73]. Ten of 18 patients
(56 %) demonstrated a tumor specific immune response,
though any correlation with outcome could not be estab-
lished due to small numbers. The same institution subse-
quently initiated a phase 2 trial combining intratumoral
DC injection and RT to 50 Gy (NCT01347034), which is
active but no longer recruiting. There is also a completed
phase 1/2 trial with results pending, combining intratu-
moral DC injection with SBRT and gemcitabine. Cur-
rently, there are no actively recruiting studies exploring
this approach.
Toll-like receptor (TLR) agonists
Irradiation activates DCs in part via the release of TLR
agonists by dying cells [74]. TLR-targeted therapy can
enhance the effect of RT by improving antigen presenta-
tion by DCs. A variety of TLR agonists have been utilized
in combination with RT in the preclinical and clinical set-
ting, including IMM-101, a suspension of Mycobacterium
that acts as a TLR-2 agonist; GLA-SE (glucopyranosyl lipid
A), a TLR-4 agonist; poly-ICLC, which binds to TLR-3;
Z-100, (ZERIA Pharmaceuticals), an extract obtained
from Mycobacterium tuberculosis strain Aoyama B, which
activates the innate immune system and modulates
macrophage activity through an unclear mechanism; CpG
(cytosine phosphate guanine), which binds to TLR9, [75]
and imiquimod, which activates TLR-7 [76, 77]. A phase 3
trial for locally advanced cervical cancer randomized pa-
tients to standard of care chemoRT versus standard of
care plus Z-100. There was a trend towards improved
overall survival with the addition of a TLR agonist [78]. A
phase 1 trial in anaplastic glioma patients administered
poly-ICLC as an intramuscular injection with RT to 60 Gy
total in daily 2 Gy fractions, and found a favorable overall
survival rate at 1 year of 69 % [79].
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CpG oligodeoxynucleotides have been shown to stimu-
late the anti-tumor immune response via TLR-9 medi-
ated DC activation. Direct intratumoral injection of CpG
has been studied with low-dose RT (2 Gy x 2) in a phase
1/2 study of mycosis fungoides patients, with a 50 % re-
sponse rate outside of the treated site (NCT00226993)
[80]. A similarly designed phase I/II study combined low
dose RT (2 Gy x 2) with intratumoral injection of CpG
in recurrent low-grade lymphoma patients, with prom-
ising response rate of 27 % in non-irradiated tumors
(NCT00185965) [81]. Overall, this approach was well
tolerated, with no treatment limiting adverse events. All
patients demonstrated a tumor-specific immune response
within 4 weeks. The combination approach of a second-
generation TLR9 agonist (SD-101) with ipilimumab and
low-dose RT is under study for low-grade lymphoma as
part of a phase 1/2 dose-escalation trial (NCT01745354).
At present, there are a handful active phase 1/2 studies
exploring use of TLR agonists with RT in lymphoma,
metastatic breast cancer and metastatic soft tissue sar-
coma (Table 4).
Cancer vaccines
Another approach for enhancing anti-tumor immunity is
vaccination through presentation of tumor antigens on
recombinant viral vectors. The combination of tumor vac-
cines with RT has shown promise in preclinical settings
and small phase 1/2 studies. Use of a poxviral-based vac-
cine to target PSA was combined with definitive RT in lo-
calized prostate cancer patients [82]. Vaccination was
administered with GM-CSF and IL-2 as immunostimula-
tory adjuvants. Out of the 17 patients who completed the
course of vaccinations, 13 exhibited at least 3-fold increase
in PSA-specific T-cells, compared to no detectable in-
crease with RT alone. There was also evidence of T-cell re-
sponses to prostate-associated antigens not present in the
vaccine, suggestive of antigenic cascade or epitope spread-
ing possibly induced by RT [83]. A subsequent phase 2
trial in 33 men with intermediate- to high-risk prostate
cancer demonstrated a detectable PSA-specific T-cell re-
sponse with vaccination [84]. Results of a phase 1 trial in
pancreatic cancer (NCT00638612) were recently reported,
[85] demonstrating the feasibility and safety of a combin-
ation approach incorporating recombinant viral vector
vaccines with chemoRT. Similar results have been shown
for a parallel approach in malignant gliomas [86]. Currently,
there is an ongoing phase 3 trial randomizing men with
localized prostate cancer to an adenoviral vector based
PSA-vaccine (ProstAtak) with definitive RT vs placebo
(NCT 01436968), and a phase 1/2 study exploring use
of a similar strategy with chemoRT in locally advanced
pancreatic cancer (NCT02446093).
There are multiple cancer vaccines under development
or recent approval, and studies combining novel vaccines
with RT to promote synergistic anti-tumor immunity are
underway. Sipuleucel-T (Provenge) is a type of cancer
vaccine consisting of autologous antigen-presenting
cells, activated ex vivo and loaded with PAP (prostatic
acid phosphatase) antigen, which is expressed by the
majority of prostate cancer cells, and GM-CSF to pro-
mote DC maturation. Sipuleucel-T has been approved
for use in metastatic, castrate-resistant prostate cancer
based on phase 3 clinical trials demonstrating improved
overall survival [87]. There are currently 3 active clin-
ical trials assessing use of radiation as an immunogenic
adjuvant in combination with sipuleucel-T (Table 4).
Clinical considerations for trial evaluation
The number of clinical trials exploring use of RT with
immunotherapy is rapidly increasing. It is evident that
RT can expose tumor antigens to the immune system,
but the optimal partnering with immunotherapies to
maximize this effect remains unclear. As we move forward,
there are several questions that remain unanswered, war-
ranting discussion of relevant considerations in appropriate
trial design and evaluation.
RT Parameters
At present, a wide range of dose and fractionation
schedules are being utilized in clinical studies, and the
optimal regimen to elicit an immune response remains
unknown. Also unclear is whether a lower RT dose is
superior to an ablative dose in this context. The appro-
priate selection of RT dose and fractionation is likely to
be a critical determinant in successful generation of an
antitumor immune response. Preclinical studies in breast
and colon cancer models suggest that 3 fractions of
8 Gy, and 5 fractions of 6 Gy, remain superior to a single
ablative dose of 20 Gy in combination with CTLA4 block-
ade to generate an abscopal response [15]. It is notable,
therefore, that clinical reports of abscopal effects after
CTLA4 blockade and RT have utilized similar regimens of
3 to 5 fractions, supporting these findings [26, 30]. While
a fractionated approach seems superior to a single dose
strategy, it remains to be determined whether ablative
doses of RT could have resulted in a similar or enhanced
response. Furthermore, since these studies were per-
formed with CTLA4 blockade, further investigations need
to be performed with other immune checkpoint inhibitors
to determine whether similar differences will be demon-
strable. Results of thoughtfully designed prospective
studies will help address this question.
The size of the treatment field also influences the part-
nership between radiation and induction of an antitumor
immune response. Circulating lymphocytes are highly
sensitive to RT, with a D90 of 0.5 Gy [88]. Larger treat-
ment fields expose a greater volume of circulating lym-
phocytes to RT, and also impact proliferating T-cells and
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potential T-cell priming in draining lymphatic regions.
Even with smaller, more conformal RT fields, pro-
tracted RT regimens expose circulating lymphocytes to
lymphotoxic doses, which may exhaust T-cells [89].
Strategies to reduce RT-induced lymphopenia include
hypo-fractionation, reduction in treatment field size
with highly conformal techniques such as SBRT/SRS
and shortening of beam-on treatment times.
Another consideration when partnering RT with im-
munotherapy is the target site. A phase 3 trial combining
a single fraction of RT to 8 Gy with CTLA-4 blockade
failed to demonstrate improved overall survival, but RT
was delivered on a single dose and directed towards an
osseous metastasis [35]. Though abscopal responses
have been seen with RT given to a bone metastasis, [90]
it is notable that most published reports demonstrating
abscopal responses have mainly resulted from RT di-
rected to visceral metastases, with multiple fractions.
Sequencing of therapies
The optimal sequencing of RT with immunotherapy
likely depends on the type of treatment used and mode
of action. All reported cases of abscopal response in
CTLA-4 blockade have occurred in patients who re-
ceived RT concurrent with, or immediately after, therapy
[15, 26, 30]. Preclinical models demonstrate that admin-
istration of RT first, followed by delayed CTLA-4 block-
ade, results in inferior outcomes, [15] supporting use of
concurrent therapy. The majority of currently ongoing
trials utilize concurrent immune checkpoint blockade
with RT. An intriguing question is whether addition of
other immunotherapies in a staged or concomitant fash-
ion can improve outcomes by promoting likelihood of
immunization against the tumor, and avoid T-cell ex-
haustion. Such an approach can incorporate RT as one
of the steps in a thoughtfully designed trial.
Trial endpoint selection
It remains to be determined whether conventional trial
endpoints such as progression-free survival, local control
and disease-free survival are relevant measures of re-
sponse to immunotherapy. As an example, patients ran-
domized to sipuleucel-T, an immunotherapeutic vaccine,
showed no objective response or improvement in time
to disease progression, yet achieved a statistically signifi-
cant 4.1 month improvement in overall survival [87].
Traditional RECIST criteria fail to account for transient
increases in tumor size, which has been known to occur
after immunotherapy, and can occur prior to a clinical
response. Furthermore, the combination of local RT and
immunotherapy can impact distant, or new lesions over
the targeted lesion. In an effort to overcome these limi-
tations, and account for changes in total tumor burden
throughout the body, immune-related response criteria
have been proposed [91, 92]. Improved methods of mon-
itoring response after immunotherapy and RT are being
developed, and clarity on relevant endpoint selection will
be obtained as data emerges from ongoing studies. At
present, overall survival, safety/toxicity and quality of
life impact appear superior to traditional endpoints of
disease/progression free survival and local control.
Patient selection
Selection of appropriate patients for trial enrollment is
critical, factors such as degree of myelosuppression,
overall tumor burden, neutrophil to lymphocyte ratio
and prior exposure to RT and chemotherapy should be
taken into consideration [43]. Depletion of immune cells
decrease likelihood of immune response; thus patients with
decreased lymphocyte counts due to cytotoxic chemother-
apy and marrow infiltration by tumor are likely to be poor
responders to treatment. Similarly, the use of larger fields
during classical prolonged fractionated regimens of 30-40
fractions inevitably will reduce the availability of effector
and memory cells [72]. In addition, tumor burden at the
time of intervention with immunotherapy and radiation
may influence outcome since patients with a significant
metastatic burden did not benefit from a combined ap-
proach of CTLA-4 blockade and RT, whereas limited
disease burden correlated with improved survival [35].
Conclusion
The combination of RT with immunotherapy has exciting
potential to transform cancer treatment by harnessing the
immune system in a synergistic approach. While evidence
in support of this combination continues to accumulate,
additional data is warranted in order to determine safety
and efficacy, and results of ongoing clinical trials will
help address this need. In addition to this, well-designed,
prospective trials will help determine the optimal dose,
technique and sequencing of RT with immunotherapies.
Development of biomarkers to predict treatment response
to immunotherapies will help identify patients most likely
to benefit from different treatments. An exciting new field
of research is developing, and results of ongoing clinical
trials are eagerly awaited.
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GY, gray; RT, radiation therapy.
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